The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Vectura and Novartis win FDA approval for COPD combo

Fri, 30th Oct 2015 08:09

(ShareCast News) - Vectura and giant Swiss partner Novartis have received US drug regulator approval for their combination treatment for patients with chronic obstructive pulmonary disease (COPD), triggering a sizeable milestone payment for the UK company.The FTSE 250 drug developer and project partner Novartis were given the green light by the US Food and Drug Administration (FDA) for the new dual combination bronchodilator Utibron Neohaler and the stand-alone monotherapy Seebri Neohaler.Utibron and Seebri are now approved for the long-term maintenance treatment of airflow obstruction in patients with (COPD), including chronic bronchitis and/or emphysema.The approval triggers a $22.5m milestone payment from Novartis to Vectura, as part of their agreement.Novartis, which elsewhere in the world saw sales of these products grew 174% to $297m in the first nine months of 2015, expects that Utibron Neohaler and Seebri Neohaler will be available in the US in the first quarter of 2016.Nearly 27m people in the US are affected by COPD, which ranks as the third leading cause of death in the US and is a major cause of serious long-term disability."The launches of Novartis' Ultibro Breezhaler and Seebri Breezhler ex-US have demonstrated the effectiveness of these products and the need for new treatment options for patients with COPD in the US," said Vectura chief executive James Ward-Lilley.He added: "Once launched, the products will bring a new royalty stream for Vectura and we look forward to confirmation from our partner in due course on their plans for the commercialisation of these products."Analysts at N+1Singer said the US FDA approval of Vectura's key COPD programmes was "an expected but very positive development. We are excited about the prospects of the LABA/LAMA class and believe that Novartis' Utibron is well placed to gain a leading share of the market alongside GSK's Anoro".Separately, Vectura announced that a €0.75m cash milestone had been triggered from partner Sandoz through the successful achievement of a further development milestone associated with asthma drug VR632 in the EU.VR632 is a generic, inhaled combination therapy for asthma/COPD delivered using Vectura's proprietary dry powder inhaler and formulation technology.
More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.